MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement. PETALING JAYA: My E.G. Services Bhd has entered into a memorandum of understanding (MoU) with Anhui Zhifei Longcom Biopharmaceutical Co Ltd to conduct phase three clinical trials and subsequent commercialisation of its Covid-19 vaccine in Malaysia. MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement. Under the terms of the contract, the companies will strive to achieve compliance to halal status requirements to secure halal certification from the Department of Islamic Development Malaysia and ensure increased acceptance from the global Muslim population. Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co Ltd which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, particularly the production of vaccines for human use. It is presently one of five Chinese companies conducting phase three clinical trials of the Covid-19 vaccine in various parts of the world. The MoU is valid for three years from the date of signing and may be further extended upon mutual agreement. The contract is not expected to have any material effect on the net asset per share and gearing of the company for financial year 2020 (FY20) but is expected to contribute positively in FY21 upon successful completion of the phase three trials and commercialisation of the vaccine.
buyappleacc.com is a professional website selling Apple Developer account for more than 3 years, choose us, provide you with the best Apple Developer account. Don't hassle, just step out.